Biogen Inc. has announced that it will present new findings at the upcoming 2025 Alzheimer's Association International Conference in Toronto, Canada, from July 27-31. The presentations will include 48-month results from the Clarity AD open-label extension study on LEQEMBI® (lecanemab), offering insights into real-world treatment and a subcutaneous formulation for maintenance dosing. Additionally, Biogen will present baseline characteristics from CELIA, a Phase 2 trial evaluating BIIB080, an investigational antisense oligonucleotide therapy targeting tau. These findings aim to advance the understanding and treatment of Alzheimer's disease. The results are set to be presented during the conference.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。